Tag Archives: frx

Forest Labs Earnings, Guidance Beat Street; Stock Up

Drugmaker Forest Laboratories (FRX) beat fiscal Q3 expectations and raised its guidance Tuesday, sending the stock to a 10-year high on the stock market today. Forest said profit in the quarter ended Dec. 31, excluding one-time items, was 27 cents a share, reversing a year-earlier loss and beating analysts’ consensus by 23 cents. Sales rose 22% to $878 million, topping estimates by more than $50 million. The company said it now expects EPS for

Forest Buying Aptalis; Teva Bids For NuPathe Vs. Endo

Drug stocks were moving on merger news in the stock market today as Forest Laboratories (FRX) forestalled an IPO and NuPathe (PATH) looked to start a bidding war between Endo Health Solutions (ENDP) and Teva Pharmaceutical Industries (TEVA). Forest Labs agreed to pay $2.9 billion for Aptalis, a drugmaker that filed to go public on Dec. 26 after a major reworking by the private equity group TPG Capital. It traded as Axcan Pharma until 2007, when